1.Sales and profit
See section β- Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.
- Kazia Therapeutics Ltd lost $13.4M in fiscal 2025.
Kazia Therapeutics Ltd
KZIA Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.
- Today
- 0.8%
- Previous close
- $7.81
- Market cap
- β
- P/E
- β
- 52-week range
-
$5.00 $16.90
Last close Β· Oct 26, 2026
$7.87
+$0.89 (+12.75%) past year
KIRAβs summary AI analyst
Hi! I read Kazia Therapeutics Ltdβs latest annual report (fiscal 2025). Here is what stands out:
1 strength 3 to watch
2.Cash and shareholders
See section β- Kazia Therapeutics Ltd returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 107.8%.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- Kazia Therapeutics Ltd has $2.6M more cash than debt.
- Kazia Therapeutics Ltd passes 2 of 8 financial health tests (Piotroski F-score).
Kazia Therapeutics Ltd in 30 seconds
Good So-so Weak
Weak
Are sales growing?
β98.2%
No. Sales fell 98.2% last year.
Weak
Does it make a profit?
β49,261.0%
No. It lost money last year.
Weak
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
β
Oct 26 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA summarises the numbers
-
Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.
Revenue
FY16
Revenue $0.3M
FY17
Revenue $0.2M
FY18
Revenue $0.1M
FY19
Revenue β
FY20
Revenue β
FY21
Revenue $11.3M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $1.5M
FY25
Revenue $0.0M
Margins, % of revenue
FY16
Gross β
Operating β
Net β2,971.3%
FCF β3,079.5%
FY17
Gross β
Operating β
Net β4,286.0%
FCF β4,598.1%
FY18
Gross β
Operating β
Net β5,075.3%
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β55.5%
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β1,160.2%
FCF β
FY25
Gross β
Operating β
Net β49,261.0%
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Kazia Therapeutics Ltd lost $13.4M in fiscal 2025.
Net income
FY16
Net income β$8.8M
FY17
Net income β$8.0M
FY18
Net income β$4.7M
FY19
Net income β$7.3M
FY20
Net income β$8.4M
FY21
Net income β$6.3M
FY22
Net income β$18.1M
FY23
Net income β$13.8M
FY24
Net income β$17.6M
FY25
Net income β$13.4M
Diluted EPS
FY16
Diluted EPS β$2.05
FY17
Diluted EPS β$1.72
FY18
Diluted EPS β$9.67
FY19
Diluted EPS β$12.77
FY20
Diluted EPS β$0.11
FY21
Diluted EPS β$0.05
FY22
Diluted EPS β$0.14
FY23
Diluted EPS β$0.08
FY24
Diluted EPS β$0.07
FY25
Diluted EPS β$0.02
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
Free cash flow
FY16
Free cash flow β$9.1M
FY17
Free cash flow β$8.6M
FY18
Free cash flow β
FY19
Free cash flow β
FY20
Free cash flow β
FY21
Free cash flow β
FY22
Free cash flow β
FY23
Free cash flow β
FY24
Free cash flow β
FY25
Free cash flow β
Cash from operations vs capital spending
FY16
Cash from operations β$8.7M
Capital spending $0.4M
FY17
Cash from operations β$8.6M
Capital spending $0.0M
FY18
Cash from operations β$6.7M
Capital spending β
FY19
Cash from operations β$4.8M
Capital spending β
FY20
Cash from operations β$5.9M
Capital spending β
FY21
Cash from operations β$6.8M
Capital spending β
FY22
Cash from operations β$16.5M
Capital spending β
FY23
Cash from operations β$10.2M
Capital spending β
FY24
Cash from operations β$6.3M
Capital spending β
FY25
Cash from operations β$8.6M
Capital spending β
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
KIRA summarises the numbers
-
Kazia Therapeutics Ltd returned $0.0M to shareholders in fiscal 2025.
The diluted share count rose 107.8%.
Dividends and buybacks
FY16
Dividends β
Buybacks β
FY17
Dividends $0.0M
Buybacks β
FY18
Dividends $0.0M
Buybacks β
FY19
Dividends $0.0M
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends $0.0M
Buybacks β
FY24
Dividends $0.0M
Buybacks β
FY25
Dividends $0.0M
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.43B
FY17
Diluted shares 0.47B
FY18
Diluted shares 0.05B
FY19
Diluted shares 0.06B
FY20
Diluted shares 0.07B
FY21
Diluted shares 0.12B
FY22
Diluted shares 0.13B
FY23
Diluted shares 0.18B
FY24
Diluted shares 0.26B
FY25
Diluted shares 0.55B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
No open-market insider trades in the last 12 months.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Kazia Therapeutics Ltd can carry it.
KIRA summarises the numbers
-
Kazia Therapeutics Ltd has $2.6M more cash than debt.
Cash vs debt (incl. leases)
FY16
Cash $24.9M
Debt β
FY17
Cash $11.1M
Debt β
FY18
Cash $4.4M
Debt β
FY19
Cash $3.8M
Debt β
FY20
Cash $6.0M
Debt β
FY21
Cash $20.7M
Debt $0.0M
FY22
Cash $5.1M
Debt $1.3M
FY23
Cash $3.5M
Debt $1.2M
FY24
Cash $1.1M
Debt $0.4M
FY25
Cash $2.8M
Debt $0.3M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $20.7M | $5.1M | $3.5M | $1.1M | $2.8M |
| Debt incl. finance leases | $0.0M | $1.3M | $1.2M | $0.4M | $0.3M |
| Debt / equity | 0.0x | 0.1x | 0.1x | β | β |
| Current ratio | 3.5x | 1.4x | 1.4x | 0.2x | 0.4x |
| Quick ratio | 3.5x | 1.4x | 1.4x | 0.2x | 0.4x |
| Total assets | $43.5M | $24.7M | $18.6M | $14.4M | $4.0M |
| Total liabilities | $15.2M | $12.1M | $10.6M | $21.0M | $9.4M |
| Shareholders' equity | $28.4M | $12.6M | $8.0M | β$6.7M | β$5.4M |
| Net debt (β = net cash) | β$20.7M | β$3.8M | β$2.3M | β$0.7M | β$2.6M |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β34.8%
Return on assets β
FY17
Return on capital β
Return on equity β36.0%
Return on assets β29.2%
FY18
Return on capital β
Return on equity β27.8%
Return on assets β19.3%
FY19
Return on capital β
Return on equity β60.8%
Return on assets β41.2%
FY20
Return on capital β
Return on equity β85.1%
Return on assets β54.5%
FY21
Return on capital β
Return on equity β33.0%
Return on assets β21.2%
FY22
Return on capital β
Return on equity β88.6%
Return on assets β53.2%
FY23
Return on capital β
Return on equity β133.9%
Return on assets β63.6%
FY24
Return on capital β
Return on equity β2,668.2%
Return on assets β106.4%
FY25
Return on capital β
Return on equity β
Return on assets β146.2%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
-
Kazia Therapeutics Ltd passes 2 of 8 financial health tests (Piotroski F-score).
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 2 / 7 | β / 6 | β / 6 | β / 6 | 1 / 8 | 2 / 8 | 3 / 8 | 2 / 8 |
| Accruals ratio | β | 2.1% | 8.4% | β14.3% | β16.0% | 1.7% | β4.8% | β16.5% | β68.4% | β52.4% |
| Altman Z'' | β | β | β | β | β | β | β | β | β | β |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.3M | $0.2M | $0.1M | β | β | $11.3M | $0.0M | $0.0M | $1.5M | $0.0M |
| Research and development | $7.2M | $8.4M | $7.6M | $4.6M | $6.4M | $10.8M | $14.6M | $10.5M | $11.4M | $4.7M |
| Interest expense | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Pretax income | β$8.8M | β$8.2M | β$4.9M | β$7.6M | β$8.6M | β$6.6M | β$18.4M | β$13.9M | β$17.7M | β$14.5M |
| Income tax | β | β$0.2M | β$0.2M | β$0.2M | β$0.2M | β$0.4M | β$0.3M | β$0.2M | β$0.2M | β$1.1M |
| Net income | β$8.8M | β$8.0M | β$4.7M | β$7.3M | β$8.4M | β$6.3M | β$18.1M | β$13.8M | β$17.6M | β$13.4M |
| Net income to common | β$8.8M | β$8.0M | β$4.7M | β$7.3M | β$8.4M | β$6.3M | β$18.1M | β$13.8M | β$17.6M | β$13.4M |
| Diluted EPS | β$2.05 | β$1.72 | β$9.67 | β$12.77 | β$0.11 | β$0.05 | β$0.14 | β$0.08 | β$0.07 | β$0.02 |
| Diluted shares | 0.43B | 0.47B | 0.05B | 0.06B | 0.07B | 0.12B | 0.13B | 0.18B | 0.26B | 0.55B |
| Cash flow | ||||||||||
| Cash from operations | β$8.7M | β$8.6M | β$6.7M | β$4.8M | β$5.9M | β$6.8M | β$16.5M | β$10.2M | β$6.3M | β$8.6M |
| Capital expenditure | $0.4M | $0.0M | β | β | β | β | β | β | β | β |
| Free cash flow | β$9.1M | β$8.6M | β | β | β | β | β | β | β | β |
| Depreciation and amortization | $0.5M | $1.1M | $1.2M | $0.8M | $0.7M | $0.9M | $1.4M | $1.3M | β | β |
| Stock-based compensation | $0.3M | $0.4M | $0.1M | $0.2M | $0.2M | $0.5M | $1.2M | $0.8M | $0.3M | $0.4M |
| Acquisitions | β | $5.4M | β | β | β | β | β | β | β | β |
| Dividends paid | β | $0.0M | $0.0M | $0.0M | β | β | β | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | β | $0.0M | $0.0M | $0.0M | β | β | β | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $24.9M | $11.1M | $4.4M | $3.8M | $6.0M | $20.7M | $5.1M | $3.5M | $1.1M | $2.8M |
| Total debt | β | β | β | β | β | $0.0M | $1.3M | $1.2M | $0.4M | $0.3M |
| Current assets | β | $15.0M | $6.8M | $5.3M | $7.3M | $22.0M | $6.5M | $7.1M | $4.1M | $3.2M |
| Current liabilities | β | $4.1M | $2.9M | $1.3M | $3.5M | $6.2M | $4.6M | $5.0M | $17.2M | $9.2M |
| Property and equipment, net | $0.4M | $0.4M | $0.0M | β | β | β | β | β | β | β |
| Intangible assets | $0.6M | $12.2M | $10.8M | $9.5M | $8.5M | $15.7M | $13.2M | $11.4M | $10.3M | $0.7M |
| Total assets | β | $27.6M | $20.8M | $14.8M | $15.8M | $43.5M | $24.7M | $18.6M | $14.4M | $4.0M |
| Total liabilities | β | $8.1M | $6.6M | $4.9M | $6.1M | $15.2M | $12.1M | $10.6M | $21.0M | $9.4M |
| Shareholders' equity | $25.2M | $19.5M | $14.2M | $9.9M | $9.7M | $28.4M | $12.6M | $8.0M | β$6.7M | β$5.4M |
| Margins | ||||||||||
| Net margin | β2,971.3% | β4,286.0% | β5,075.3% | β | β | β55.5% | β | β | β1,160.2% | β49,261.0% |
| FCF margin | β3,079.5% | β4,598.1% | β | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on equity | β34.8% | β36.0% | β27.8% | β60.8% | β85.1% | β33.0% | β88.6% | β133.9% | β2,668.2% | β |
| Return on assets | β | β29.2% | β19.3% | β41.2% | β54.5% | β21.2% | β53.2% | β63.6% | β106.4% | β146.2% |
| Return on tangible equity | β35.6% | β111.1% | β135.9% | β1,495.4% | β710.9% | β49.8% | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β36.5% | β50.9% | β | β | β | β100.0% | β | β | β98.2% |
| Share count change | β | 9.5% | β89.7% | 18.9% | 27.0% | 61.1% | 12.6% | 39.1% | 43.1% | 107.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | 0.0x | 0.1x | 0.1x | β | β |
| Current ratio | β | 3.6x | 2.4x | 4.0x | 2.1x | 3.5x | 1.4x | 1.4x | 0.2x | 0.4x |
| Quick ratio | β | 3.6x | 2.4x | 4.0x | 2.1x | 3.5x | 1.4x | 1.4x | 0.2x | 0.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 128.6% | 4.8% | β | β | β | β | β | β | β | β |
| Stock comp / revenue | 91.6% | 207.7% | 138.7% | β | β | 4.2% | β | β | 23.1% | 1,553.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 2.0 | β | β | β | 1.0 | 2.0 | 3.0 | 2.0 |
| Accruals ratio | β | 2.1% | 8.4% | β14.3% | β16.0% | 1.7% | β4.8% | β16.5% | β68.4% | β52.4% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001075880). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only β not investment advice. Check the original filings before relying on any figure.